A Randomized OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation

A Randomized  OPen-label Active controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation

Brief description of study

In order to achieve 200 per-protocol subjects, approximately 250 eligible subjects, age 18 years or older, with a history of paroxysmal or persistent NVAF who are scheduled to undergo an elective catheter ablation procedure will randomize in a 1:1 ratio to receive either rivaroxaban 20 mg orally, once-daily, preferably administered with the evening meal or uninterrupted VKA (adjusted to achieve a recommended INR of 2.0 to 3.0). Subjects not randomized to the rivaroxaban arm of the study will be initiated on, transitioned to (if not already on a VKA) or will continue to receive their usual care regimen of uninterrupted VKA.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Atrial Fibrillation
  • Age: Between 1 Years - 99 Years
  • Gender: All


Updated on 01 Dec 2023. Study ID: 817681

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center